Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Intellective Biologics Raises Over RMB500m in Series C Financing Round

Fineline Cube Aug 5, 2022

China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly...

Company Deals

MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development

Fineline Cube Aug 5, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...

Company Deals

invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19

Fineline Cube Aug 5, 2022

invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...

Company Drug

Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China

Fineline Cube Aug 5, 2022

US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...

Company

BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple

Fineline Cube Aug 5, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...

Company Deals

Innovent Biologics and Sanofi Announce License Deal for Drug Development in China

Fineline Cube Aug 5, 2022

China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...

Company

Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge

Fineline Cube Aug 5, 2022

US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...

Company

Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip

Fineline Cube Aug 5, 2022

Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration

Fineline Cube Aug 5, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...

Company Drug

Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment

Fineline Cube Aug 5, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study

Fineline Cube Aug 5, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...

Company Deals

HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization

Fineline Cube Aug 5, 2022

China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...

Company

Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved

Fineline Cube Aug 5, 2022

Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...

Company Drug

Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review

Fineline Cube Aug 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...

Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Company Drug

Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study

Fineline Cube Aug 4, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...

Company Medical Device

Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...

Company Medical Device

Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...

Company Deals

Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues

Fineline Cube Aug 4, 2022

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...

Posts pagination

1 … 692 693 694 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.